Exploring complement-dependent cytotoxicity by rituximab isotypes in 2D and 3D-cultured B-cell lymphoma

BACKGROUND: The therapeutic IgG1 anti-CD20 antibody, rituximab (RTX), has greatly improved prognosis of many B-cell malignancies. Despite its success, resistance has been reported and detailed knowledge of RTX mechanisms are lacking. Complement-dependent cytotoxicity (CDC) is one important mode of a...

Descripción completa

Detalles Bibliográficos
Autores principales: Lara, Sandra, Heilig, Juliane, Virtanen, Alexander, Kleinau, Sandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210731/
https://www.ncbi.nlm.nih.gov/pubmed/35725455
http://dx.doi.org/10.1186/s12885-022-09772-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9210731/
https://www.ncbi.nlm.nih.gov/pubmed/35725455
http://dx.doi.org/10.1186/s12885-022-09772-1

Ejemplares similares